Details

Autor(en) / Beteiligte

• Ferro, Matteo
• Del Giudice, Francesco
• Carrieri, Giuseppe
• Busetto, Gian Maria
• Cormio, Luigi
• Hurle, Rodolfo
• Contieri, Roberto
• Arcaniolo, Davide
• Sciarra, Alessandro
• Maggi, Martina
• Porpiglia, Francesco
• Manfredi, Matteo
• Fiori, Cristian
• Antonelli, Alessandro
• Tafuri, Alessandro
• Bove, Pierluigi
• Terrone, Carlo
• Borghesi, Marco
• Costantini, Elisabetta
• Iliano, Ester
• Montanari, Emanuele
• Boeri, Luca
• Russo, Giorgio Ivan
• Madonia, Massimo
• Tedde, Alessandro
• Veccia, Alessandro
• Simeone, Claudio
• Liguori, Giovanni
• Trombetta, Carlo
• Brunocilla, Eugenio
• Schiavina, Riccardo
• Dal Moro, Fabrizio
• Racioppi, Marco
• Vartolomei, Mihai Dorin
• Longo, Nicola
• Spirito, Lorenzo
• Crocetto, Felice
• Cantiello, Francesco
• Damiano, Rocco
• Di Stasi, Savino M.
• Marchioni, Michele
• Schips, Luigi
• Parma, Paolo
• Carmignani, Luca
• Conti, Andrea
• Soria, Francesco
• Gontero, Paolo
• Barone, Biagio
• Deho, Federico
• Zaffuto, Emanuele
• Papalia, Rocco
• Scarpa, Roberto M.
• Pagliarulo, Vincenzo
• Lucarelli, Giuseppe
• Ditonno, Pasquale
• Botticelli, Francesco Maria Gerardo
• Musi, Gennaro
• Catellani, Michele
• de Cobelli, Ottavio

Titel

The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis

Ist Teil von

• Cancers, 2021-10, Vol.13 (21), p.5276

Ort / Verlag

Basel: MDPI AG

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Background: To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). Methods: A retrospective analysis was performed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 2019 and February 2021, followed by Re-TURBT and/or adjuvant intravesical BCG. Results: A total of 2591 patients from 27 institutions with primary TURBT were included. Of these, 1534 (59.2%) and 1056 (40.8%) underwent TURBT before and during the COVID-19 outbreak, respectively. Time between diagnosis and TURBT was significantly longer during the COVID-19 period (65 vs. 52 days, p = 0.002). One thousand and sixty-six patients (41.1%) received Re-TURBT, 604 (56.7%) during the pre-COVID-19. The median time to secondary resection was significantly longer during the COVID-19 period (55 vs. 48 days, p < 0.0001). A total of 977 patients underwent adjuvant intravesical therapy after primary or secondary resection, with a similar distribution across the two groups (n = 453, 86% vs. n = 388, 86.2%). However, the proportion of the patients who underwent maintenance significantly differed (79.5% vs. 60.4%, p < 0.0001). Conclusions: The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated.